Overview

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Status:
Active, not recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving nivolumab in addition to temozolomide plus radiation therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Ono Pharmaceutical Co. Ltd

Treatments:

Antibodies, Monoclonal
Dacarbazine
Nivolumab
Temozolomide